– CRISPR-based CAR-T cell therapy candidates targeting CD19+, BCMA and CD70 demonstrate high editing rates, and potent anti-tumor activity in preclinical models –
– Expanding applicability of CRISPR-based CAR-T therapy to solid tumors –
– CRISPR-based CAR-T cell therapy candidates targeting CD19+, BCMA and CD70 demonstrate high editing rates, and potent anti-tumor activity in preclinical models –
– Expanding applicability of CRISPR-based CAR-T therapy to solid tumors –